Sun Pharmaceutical Industries

Stories

FDA approves ILUMYA for psoriatic arthritis, adding an in-office IL-23 option

Markets ILUMYA in the United States

On October 30, 2026, the Food and Drug Administration approved ILUMYA for adults with active psoriatic arthritis. The drug, tildrakizumab, had been cleared since 2018 only for plaque psoriasis, a skin condition.

Updated 1 hour ago

Generic semaglutide floods India as patent expires, cutting prices up to 90%

New Capabilities

As of May 2026: Major generic semaglutide launcher after winning partial Delhi High Court ruling

Only 200,000 of India's roughly 250 million people living with obesity have ever taken a GLP-1 receptor agonist—the class of drugs that includes Novo Nordisk's blockbuster Ozempic and Wegovy. On March 21, the day after Novo's last Indian patent expired, more than 40 companies began selling generic semaglutide at prices as low as 1,290 rupees a month (about $15, compared to $100–175 for the branded versions). It is the largest single-day generic launch in Indian pharmaceutical history.

Updated May 30